Alzheimer's Disease Against A Cancer

Alzheimer's Disease Against A Cancer.


Although a investigate in 2012 suggested a cancer narcotic could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now judge they have been unable to duplicate those findings. The teams said their enquire could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has consequential side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash nuskhe. "Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer poison with stark side effects," said study co-author Robert Vassar, a professor of room and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.



This routine should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering clobber of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to play host to refractory cutaneous T-cell lymphoma tablet. Once approved, however, the cure-all also was available by prescription for "off-label" uses.



The 2012 study suggested that bexarotene was able to like reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the monogram study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the circumstance of Alzheimer's. Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the modern development research, admitted being skeptical about the initial findings.



"We were surprised and excited - even stunned - when we foremost saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center flash release. "The mechanism of action made some sense, but the declaration that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too satisfactory to be true".



In attempting to duplicate the findings, the research teams found that they were of course too good to be true. "We all went back to our labs and tried to confirm these promising findings. We repeated the incipient experiments - a standard process in science. Combined results are really distinguished in this field.



None of us found anything like what they described in the 2012 paper". Researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St Louis and the University of Tubingen in Germany reported in the May 24, 2013 appear of the roll Science that they did not find any reduction in beta amyloid plaques during or after therapy with bexarotene in three different strains of mice. Bexarotene has never been tested on public as a treatment for Alzheimer's disease medicine. Currently, there is no cure or effective treatment for the ongoing condition, which affects an estimated 5,3 million Americans.

tag : bexarotene university study alzheimer three chicago findings treatment research

Post a comment

Private comment

Profile

ivankuleshov

Author:ivankuleshov
Welcome to FC2!

Latest journals
Latest comments
Latest trackbacks
Monthly archive
Category
Search form
Display RSS link.
Link
Friend request form

Want to be friends with this user.